Prenyltransferase inhibitors induce apoptosis in proliferating thyroid cells through a p53-independent, CrmA-sensitive, and caspase-3-like protease- dependent mechanism

Endocrinology

Volumn 140, Issue 2, 1999, Pages 698-704

  Vitale, Mario ^a,c   Di Matola, Tiziana ^a   Rossi, Guido ^a,b   Laezza, Chiara ^a   Fenzi, Gianfranco ^a   Bifulco, Maurizio ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c Dipto di Biol e Fatologia C   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYLALLYLTRANSFERASE; PROTEIN P53; PROTEINASE;

APOPTOSIS; ARTICLE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRENYLATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; THYROID GLAND;

EID: 0032911004     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.140.2.6494     Document Type: Article

References (44)

1. 1. Cohen JJ 1993 Apoptosis. Immunol Today 14:126-130
2. 2. Ellis RE, Yuan JY, Horvitz HR 1991 Mechanisms and functions of cell death. Annu Rev Cell Biol 7:663-698
3. 3. Yamaguchi Y, Suda T, Ohta S, Tominaga K, Miura Y, Kasahara T 1991 Analysis of the survival of mature human eosinophils: interleukin-5 prevents apoptosis in mature human eosinophils. Blood 78:2542-2547
4. 4. Dremier S, Golstein J, Mosselmans R, Dumont JE, Caland P, Robaye B 1994 Apoptosis in dog thyroid cells. Biochem Biophys Res Commun 200:52-58
5. 5. Di Jeso B, Ulianich L, Racioppi L, D'Armiento F, Feliciello A, Pacifico F, Consiglio E, Formisano S 1995 Serum withdrawal induces apoptotic cell death in Ki-ras transformed but not in normal differentiated thyroid cells. Biochem Biophys Res Commun 214:819-824
6. 6. Vitale M, Di Matola T, Fenzi GF, Illario M, Rossi G 1998 Fibronectin is required to prevent thyroid cell apoptosis through an integrin-mediated adhesion mechanism. J Clin Endocrinol Metab 83:3673-3080
7. 7. Lowe SW, Ruley HE, Jacks T, Housman DE 1993 p53-dependent apoptosis mudulates the cytotoxicity of anticancer agents. Cell 74:957-967
8. 8. Miyashita T, Reed JC 1995 Tumor suppressor p53 is a direct transcriptional activator of human bax gene. Cell 80:293-299
9. 9. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B 1992 Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827-830
10. 10. Liebermann DA, Hoffman B, Steinman RA1995 Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene 11:199-210
11. 11. Jones KD, Couldwell WT, Hinton DR, Su Y, He S, Anker L, Law RE 1994 Lovastatin induces growth inhibition and apoptosis in human malignant glioirta cells. Biochem Biophys Res Commun 205:1681-1687
12. 12. Sebti SM, Hamilton AD 1997 Inhibition of Ras prenylation: a novel approach to cancer chemotherapy. Pharmacol Ther 74:103-114
13. 13. Lerner EC, Hamilton AD, Sebti SM 1997 Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design. Anticancer Drug Des. 12:229-238
14. 14. Padayatty SJ, Marcelli M, Shao TC, Cunningham GR 1997 Lovastatin in-duced apoptosis in prostate stromai cells. J Clin Endocrinol Metab 82:1434-1439
15. 15. Sun J, Qian Y, Hamilton AD, Sebti SM 1998 Both farnesyltransferase and geranylgeranyltransferasc I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 16:1467-1473
16. 16. Lebowitz PF, Sakamuro D, Prendergast GC 1997 Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res 57:708-713
17. 17. Ghosh PM, Mott GE, Ghosh-Choudhury N, Radnik RA, Stapleton ML, Ghidoni JJ, Kreisberg JI 1997 Lovastatin induces apoptosis by inhibiting mitotic and post-mitotic events in cultured mesangial cells. Biochim Biophys Acta 1359:13-24
18. 18. Fagin JA 1992 Genetic basis of endocrine disease. III. Molecular defects in thyroid gland neoplasia. J Clin Endocrinol Metab 75:1398-1400
19. 19. Wynford-Thomas D 1993 Molecular basis of epithelial tumorigenesis: the thyroid model. Crit Rev Oncogen 4:1-23
20. 20. Santoro M, Grieco M, Melillo RM, Fusco A, Vecchio G 1995 Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation. Eur J Endocrinol 133:513-522
21. 21 . Suarez HG, du Villard JA, Severino M, Caillou B, Schlumberger M, Tubiana M, Parmentier C, Monier R 1990 Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 5:565-570
22. 22. Vitale M, Illario M, Di Matola T, Casamassima A, Fenzi GF, Rossi G 1997 Integrin binding to immobilized collagen and fibronectin stimulates the proliferation of human thyroid cells in culture. Endocrinology 138:1642-1648
23. 23. Bifulco M, Laezza C, Aloj SM, Garbi C 1993 Mevalonate controls cytoskeleton organization and cell morphology in thyroid epithelial cells. J Cell Physiol 155:340-348
24. 24. Nagata S, Golstein P 1995 The Fas death factor. Science 267:1449-1456
25. 25. Stimac E, Housman D, Huberman JA 1977 Effects of inhibition of protein synthesis on DNA replication in cultured mammalian cells. J Mol Biol 115:485-511
26. 26. Salvesen GS, Dixit VM 1997 Caspases: intracellular signaling by proteolysis. Cell 91:443-446
27. 27. Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry N A, Wong WW, Yuan J 1996 Human ICE/CED-3 protease nomenclature. Cell 87:171
28. 28. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, Aunins J, Ellison KO, Ayala YM, Casano FJ, Chin J, Ding GJ-F, Egger LA, Saffney E, Limjuco G, Palyha OC, Raju SM, Rolando AM, Salley JP, Yamin T-T, Lee TD, Shively JE, MacCross M, Mumford RA, Schidt J A, Tocci MJ 1992 A novel heterodimeric cysteine protease is required for interleukin-lß processing in monocytes. Nature 356:768-774
29. 29 Faucheu C, Diu A, Chan AW, Blanche! AM, Miossec C, Herve F, Collard-DutilleuI V, Gu Y, Aldape RA, Lippke JA, Rocher C, Su MSS, Livingstone DJ, Hercend T, Lalanne J-L 1995 A novel human protease similar to the interleukin-lß converting enzyme induces apoptosis in transfected cells. EMBOJ 14:1914-1922
30. 30. Munday NA, Vaillancourt JP, Ali A, Casano FJ, Miller DK, Molineaux SM, Yamin TT, Yu VL, Nicholson DW 1995 Molecular cloning and pro-apoptotic activity of FCErelH and ICErellll, members of the ICE/CED-3 family of cysteine proteases. J Biol Chem 270:15870-15876
31. 31. Tewari M, Dixit VM 1995 Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product. J Biol Chem 270:3255-3260
32. 32. Gagliardini V, Fernandez PA, Lee RK, Drexler HC, Rotello RJ, Fishman MC, Yuan J 1944 Prevention of vertebrate neuronal death by the crmA gene. Science 263:826-828
33. 33. Frisch SM, Vuori K, Kelaita D, Sicks S 1996 A role for Jun-N-terminal kinase in anoikis; suppression by bcl-2 and crmA. J Cell Biol 135:1377-1382
34. 34. Geiey S, Hartmann BL, Kapelari K, Egle A, Viliunger A, Heidacher D, Greil R, Auer B, Kofler R 1997 The interleukin lß-converting enzyme inhibitor CrmA prevents Apol/Fas- but not glucocorticoid-induced poly(ADP-ribose) polymerase cleavage and apoptosis in lymphoblastic leukemia cells. FEBS Lett 402:36-40
35. 35. Datta R, Kojima H, Banach D, Bump NJ, Talanian RV, Alnemri ES, Weichselbaum RR, Wong WW, Kufe DW 1997 Activation of a CrmA-insensifive, p35-sensitive pathway in ionizing radiation-induced apoptosis.J Biol Chem 272:1965-1969
36. 36. Ray CA, Black RA, Kronheim SR, Greenstreet TA, Sleath PR, Salvesen GS, Pickup DJ 1992 Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1 beta converting enzyme. Cell 69:597-604
37. 37. Zhou Q, Snipas S, Orth K, Muzio M, Dixit VM, Salvesen GS 1997 Target protease specificity of the viral serpin CrmA. Analysis of five caspases. J Biol Chem 272:7797-7800
38. 38 Kamada S, Washida M, Hasegawa J, Kasino H, Funahashi Y, Tsujimoto Y 1997 Involvement of caspase-4(-like) protease in Fas-mediated apoptotic path-way. Oncogene 15:285-290
39. 39. Villa P, Kaufmann SH, Eamshaw WC 1997 Caspases and caspase inhibitors. Trends Biochem Sci 22:388-393
40. 40. Armstrong RC, Aja T, Xiang J, Gaur S, Krebs JF, Hoang K, Bai X, Korsmeyer SJ, Karanewsky DS, Fritz LC, Tomaselli KJ 1996 Fas-induced activation of the cell death-related protease CPP32 Is inhibited by Bcl-2 and by ICE family protease inhibitors. J Biol Chem 271:16850-16855
41. 41. Hirata H, Takahashi A, Kobayashi 5, Yonehara S, Sawai H, Okazaki T, Yamamoto K, Sasada M 1998 Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J Exp Med 187:587-600
42. 42. Srinivasula SM, Ahmad M, Femandes-Alnemri T, Alnemri ES 1998 Auto-activation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell 1:949-957
43. 43. Marcelli M, Cunningham GR, Haidacher SJ, Padayatty SJ, Sturgis L, Kagan C, Denner L 1998 Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res 58:76-83
44. 44. Chang MY, Jan MS, Won SJ, Liu HS 1998 Ha-rasVall2 oncogene increases susceptibility of NIH/3T3 cells to lovastatin. Biochem Biophys Res Commun 248:62-68